1. Scrip
  2. >>Drug Pricing

Pricing Tensions Escalate In India; Novartis Under A Cloud

 
• By Anju Ghangurde

Charges of price collusion pertaining to Novartis’ Galvus are the latest in a string of allegations that have rocked the pharmaceutical industry in India over the recent past, though the company claims it has not flouted the law. Industry is also under fire for ‘suspected’ deviations from mandated price caps for over 600 medicines – a charge seen widening the trust deficit.

Novartis AG finds itself in a spot in India after a whistle-blower alleged that the Swiss multinational and its licensees for Galvus (vildagliptin) have colluded to set prices of the product in the country.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Mounjaro In India: Price Differential, Window Of Opportunity

 
• By Anju Ghangurde

Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?

Stelara Biosimilars Storm US Market With 85% Discounts Ahead Of Price Drop In Medicare

 
• By Cathy Kelly

The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.

More from Scrip

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.